

ASSOCIATIONS BETWEEN PITUITARY ABNORMALITIES AND TREATMENT RESPONSE IN CHILDREN WITH GROWTH HORMONE DEFICIENCY

First multicenter study in Portugal

Catarina Diamantino¹, Ana Sofia Simões², Catarina Borges¹, Carla Costa³, Carla Pereira⁴, Paula Vieira⁵, Ana Luísa Leite⁶, Ana Cristina Monteiro⁷, Joana Freitas⁸, Sandrina Novais⁹, Teresa Bernardo⁹, Marcelo Fonseca¹⁰, Alice Mirante²

¹Department of Pediatric Endocrinology and Diabetes - Hospital de Dona Estefânia- Centro Hospitalar Universitário Lisboa Central; ²Department of Pediatric Endocrinology and Diabetes - Hospital Pediátrico de Coimbra; ³Department of Pediatric Endocrinology and Diabetes - Centro Hospitalar Universitário de São João, ⁴Department of Pediatric Endocrinology and Diabetes - Centro Hospitalar Universitário Lisboa Norte; ⁵Department of Pediatric Endocrinology and Diabetes - Hospital São Francisco Xavier, Centro Hospitalar Universitário Lisboa Ocidental; ⁶Department of Pediatric Endocrinology and Diabetes - Centro Hospitalar Vila Nova de Gaia; ⁷Department of Pediatric Endocrinology and Diabetes - Hospital Professor Doutor Fernando Fonseca; ⁸Department of Pediatric Endocrinology and Diabetes - Centro Materno Infantil do Norte, Centro Hospitalar do Porto; ⁹Department of Pediatric Endocrinology and Diabetes - Unidade Local de Saúde do Alto Minho; ¹⁰Department of Pediatric Endocrinology and Diabetes - Hospital Pedro Hispano, Matosinhos

Background/Aims:

Magnetic resonance imaging (MRI) is used to investigate the etiology of growth hormone deficiency (GHD). There is a close relationship between structural changes in the pituitary gland and clinical status.

We aimed to investigate the relationship between MRI findings and clinical symptoms and treatment response in children with GHD

Methods:

- Retrospective study; Multicenter (9 Department of Pediatric Endocrinology of Portugal)
- Data collection: 2006-2016
- Inclusion criteria: GHD children treated for at least two years whose magnetic resonance imaging was available.
- Exclusion criteria: children born small for gestational age, chromosomal/dysmorphic syndromes, bone dysplasia, chronic systemic diseases and acquired GHD
- Clinical presentation, hormonal status and first year growth response were compared between patients with pituitary abnormalities and patients with normal MRI.
- Data were shown in mean± standart deviation

Results:

Table 1. Clinical findings of the patients in the study		Table 2. Pituitary MRI with pathological findings	
Number of patients	321	Isolated abnormalities	68
Male/Female	217 / 104	• Hypoplastic anterior pituitary	43 (63%)
Isolate GHD/Multiple pituitary hormone deficiencies	279 (87%) / 42 (13%)	• Thin pituitary stalk	10 (15%)
Target height SDS	-0,87 ± 0,86	• Ectopic posterior pituitary	6 (9%)
Pituitary MRI normal/Pituitary MRI with pathological findings	180 (56%) / 141 (44%)	• Others	9 (13%)
At start of GH treatment:		Two abnormalities	42
• Age (year)	9,68 ± 4	Ectopic posterior pituitary+Aplasia / Hypoplastic anterior pituitary+stalk defects	31
• Bone age (year)	7.5 ± 6,3		
• Height SDS	-3,05 ± 1,03		
• BMI SDS	-0,28 ± 0,6		
• GH dose (mcg/kg/d)	27,5 ± 4,4		

Table 3. Comparison of auxologic parameters in patients with pituitary MRI normal and patients with pituitary MRI with pathological findings before and after 12 months of GH therapy

	Pituitary MRI Pathology - 180 (56,1%)	Pituitary MRI Pathology + 141 (43,9%)	p
At start of GH treatment:			
• Age (year)	10,61 ± 3,7	8,5 ± 4,18	0,000*
• Height SDS	-2,77 ± 0,84	-3,02 ± 1,2	0,001**
First year GH treatment:			
• Height SDS	-2,25 ± 0,91	-2,42 ± 1,27	0,351**
• Height velocity SDS	00,48 ± 0,57	0,77 ± 1,04	0,001**

* Student's t test; ** Mann Whitney U test

Conclusions:

MRI is a useful tool in assessing GHD patients. The presence and type of hypothalamic-pituitary abnormalities provides valuable information regarding the likely severity of the GHD and predicting treatment response.

Bibliography: N Di Iorgi et al. Classical and non-classical causes of GH deficiency in the paediatric age. Best Practice & Research Clinical Endocrinology & Metabolism 30 (2016) 705e736; Delman B. Imaging of pediatric pituitary abnormalities, Endocrinol Metab Clin N Am, 2009;38:673-98; Deal C et al. Associations between pituitary imaging abnormalities and clinical and biochemical phenotypes in children with congenital growth hormone deficiency: data from an international observational study, Hormone Research in Paediatrics, 2013; 79:283-292; Kalina MA, Faska BK, Gruszczynska K, Baron J, Tendera EM. Usefulness of magnetic resonance findings of the hypothalamic-pituitary region in the management of short children with growth hormone deficiency: evidence from a longitudinal study; Childs Nerv Syst, 2012; 28:121-127